These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 15041355)
1. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation. Casanovas Taltavull T Transplant Proc; 2004 Mar; 36(2 Suppl):291S-294S. PubMed ID: 15041355 [TBL] [Abstract][Full Text] [Related]
2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172 [TBL] [Abstract][Full Text] [Related]
3. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. Rayhill SC; Barbeito R; Katz D; Voigt M; Labrecque D; Kirby P; Miller R; Stolpen A; Wu Y; Schmidt W Transplant Proc; 2006 Dec; 38(10):3625-8. PubMed ID: 17175350 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Cantarovich M; Tzimas GN; Barkun J; Deschênes M; Alpert E; Tchervenkov J Transplantation; 2003 Jul; 76(1):98-102. PubMed ID: 12865793 [TBL] [Abstract][Full Text] [Related]
11. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients. Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391 [TBL] [Abstract][Full Text] [Related]
12. Hot topic in hepatitis C virus research: the type of immunosuppression does not matter. Berenguer M Liver Transpl; 2011 Nov; 17 Suppl 3():S24-8. PubMed ID: 21634004 [TBL] [Abstract][Full Text] [Related]
14. Immunosuppression and outcomes of patients transplanted for hepatitis C. Lake JR J Hepatol; 2006 Apr; 44(4):627-9. PubMed ID: 16503080 [No Abstract] [Full Text] [Related]
15. Optimizing the immunosuppressive regimen in heart transplantation. Eisen H; Ross H J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807 [TBL] [Abstract][Full Text] [Related]
17. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation. Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691 [TBL] [Abstract][Full Text] [Related]
18. The impact of cyclosporine on the development of immunosuppressive therapy--pediatric transplantation using cyclosporine. Hoyer PF; Vester U Transplant Proc; 2004 Mar; 36(2 Suppl):197S-202S. PubMed ID: 15041336 [TBL] [Abstract][Full Text] [Related]
19. History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion. Cantarovich M; Barkun J; Giannetti N; Cecere R; Besner JG; Tchervenkov J Transplant Proc; 2004 Mar; 36(2 Suppl):442S-447S. PubMed ID: 15041383 [TBL] [Abstract][Full Text] [Related]
20. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Tjon AS; Sint Nicolaas J; Kwekkeboom J; de Man RA; Kazemier G; Tilanus HW; Hansen BE; van der Laan LJ; Tha-In T; Metselaar HJ Liver Transpl; 2010 Jul; 16(7):837-46. PubMed ID: 20583092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]